Sep 2026· Parkinsonism & Related Disorders· Vol 152, pp.
108962
· 0 citations· 62 references
Medicine
TL;DR
Four therapeutic approaches that are likely to influence PD management in the coming years are discussed: continuous subcutaneous levodopa infusion, cell-based dopamine replacement, immunotherapies targeting α-synuclein, and gene transfer therapies.
Abstract
Recent advances in Parkinson's disease (PD) therapeutics have generated new opportunities for both symptomatic and disease-modifying treatments. This review discusses four therapeutic approaches that are likely to influence PD management in the coming years: continuous subcutaneous levodopa infusion, cell-based dopamine replacement, immunotherapies targeting α-synuclein, and gene transfer therapies. Subcutaneous levodopa infusion systems have recently demonstrated efficacy in reducing motor fluctuations and represent an important advance toward more physiological dopamine replacement. Stem cell-derived dopaminergic progenitors have revitalized cell replacement research and demonstrated encouraging safety and feasibility in early clinical trials. Although first-generation anti-α-synuclein antibodies have not demonstrated definitive clinical benefit, advances in antibody engineering and biomarker-guided patient selection may help clarify their therapeutic potential. Improvements in viral vector design and delivery are enabling increasingly sophisticated gene-based therapies for both sporadic and genetics forms of PD. Collectively, these advances are expanding therapeutic options and shaping the future management of PD.
This review focuses on some of the groundbreaking advances and the immediate challenges faced by researchers, clinicians, and individuals with PD, as they collaborate to address the great-and ever-growing-clinical need in PD.
Grażyna Söderbom· International review of neur...· 0 citations
This review summarizes the metabolism, physiological functions, and pathophysiology of dopamine in the striatum and discusses clinical studies investigating gene transfer of dopamine-synthesizing enzymes into the striatum.
H. Ichinose, Yo Sato, Shin-ichi Muramatsu· Expert Opinion on Biological...· 0 citations
This article reviews current prospects for disease-modifying therapy in Parkinson’s Disease, with a focus on genotype-targeted treatments for the condition. Over 100 genes and loci are implicated in the pathogenesis of PD. They have varied cellular functions and studies of these roles have yielded insights into the mec...
George Ransley, A. Schapira· Current Treatment Options in...· 0 citations
Over the past five decades, strategies for dopaminergic therapy in Parkinson's disease (PD) have evolved significantly. Historically treatments aimed to reduce parkinsonism symptoms. Later, the focus shifted to preventing motor fluctuations and dyskinesias, leading clinicians to delay levodopa initiation. As knowledge...
M. R. Nodel· Zhurnal Nevrologii i Psikhia...· 0 citations
Emerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed.
Moein Amin, Kaitlyn N. Palmer, A. Samara et al.· Drugs· 0 citations
Background/Objectives: Parkinson’s disease (PD) is characterized by the selective loss of nigrostriatal dopaminergic neurons, accompanied by the accumulation and spreading of misfolded α-synuclein aggregates. Proposed mechanisms relevant to PD include gut–brain propagation of pathology via autonomic circuits, autophagy...
Christian Schmidt, Christian Hundeshagen, S. Mihm· Neurology International· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.